A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID 1195297
Author(s) Suwaki, Natsuko; Vanhecke, Elsa; Atkins, Katelyn M; Graf, Manuela; Swabey, Katherine; Huang, Paul; Schraml, Peter; Moch, Holger; Cassidy, Amy Mulick; Brewer, Daniel; Al-Lazikani, Bissan; Workman, Paul; De-Bono, Johann; Kaye, Stan B; Larkin, James; Gore, Martin E; Sawyers, Charles L; Nelson, Peter; Beer, Tomasz M; Geng, Hao; Gao, Lina; Qian, David Z; Alumkal, Joshi J; Thomas, Gary; Thomas, George V
Author(s) at UniBasel Schraml, Peter Hans
Year 2011
Title A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma
Journal Science translational medicine
Volume 3
Number 85
Pages / Article-Number 85ra47
Abstract Metastatic renal cell carcinoma (RCC) is a molecularly heterogeneous disease that is intrinsically resistant to chemotherapy and radiotherapy. Although therapies targeted to the molecules vascular endothelial growth factor and mammalian target of rapamycin have shown clinical effectiveness, their effects are variable and short-lived, underscoring the need for improved treatment strategies for RCC. Here, we used quantitative phosphoproteomics and immunohistochemical profiling of 346 RCC specimens and determined that Src kinase signaling is elevated in RCC cells that retain wild-type von Hippel-Lindau (VHL) protein expression. RCC cell lines and xenografts with wild-type VHL exhibited sensitivity to the Src inhibitor dasatinib, in contrast to cell lines that lacked the VHL protein, which were resistant. Forced expression of hypoxia-inducible factor (HIF) in RCC cells with wild-type VHL diminished Src signaling output by repressing transcription of the Src activator protein tyrosine phosphatase 1B (PTP1B), conferring resistance to dasatinib. Our results suggest that a HIF-regulated VHL-PTP1B-Src signaling pathway determines the sensitivity of RCC to Src inhibitors and that stratification of RCC patients with antibody-based profiling may identify patients likely to respond to Src inhibitors in RCC clinical trials.
Publisher American Association for the Advancement of Science
ISSN/ISBN 1946-6234
edoc-URL http://edoc.unibas.ch/dok/A6005480
Full Text on edoc No
Digital Object Identifier DOI 10.1126/scitranslmed.3002004
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/21632985
ISI-Number WOS:000292980100003
Document type (ISI) Journal Article

MCSS v5.8 PRO. 0.458 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |